Anupam Rama
Stock Analyst at JP Morgan
(3.36)
# 964
Out of 4,944 analysts
266
Total ratings
43.26%
Success rate
4.13%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Anupam Rama
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VERA Vera Therapeutics | Maintains: Overweight | $56 → $53 | $21.14 | +150.71% | 10 | Aug 7, 2025 | |
| COGT Cogent Biosciences | Maintains: Overweight | $29 → $30 | $11.56 | +159.63% | 7 | Aug 7, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Overweight | $35 → $37 | $23.90 | +54.81% | 17 | Aug 4, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Neutral | $140 → $145 | $128.89 | +12.50% | 18 | Jul 31, 2025 | |
| RAPT RAPT Therapeutics | Upgrades: Neutral | $14 | $10.90 | +28.44% | 8 | Jul 30, 2025 | |
| SRPT Sarepta Therapeutics | Upgrades: Neutral | $24 | $18.80 | +27.66% | 17 | Jul 29, 2025 | |
| IDYA IDEAYA Biosciences | Maintains: Overweight | $66 → $72 | $23.62 | +204.89% | 9 | Jul 28, 2025 | |
| ANAB AnaptysBio | Maintains: Overweight | $42 → $80 | $20.09 | +298.21% | 12 | Jul 24, 2025 | |
| REPL Replimune Group | Downgrades: Neutral | $19 → $9 | $5.25 | +71.43% | 10 | Jul 22, 2025 | |
| OLMA Olema Pharmaceuticals | Maintains: Overweight | $30 → $28 | $5.31 | +427.31% | 4 | Mar 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $104 → $117 | $28.11 | +316.22% | 3 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $44 → $50 | $49.09 | +1.85% | 9 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $41 | $12.97 | +216.11% | 10 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $44 → $51 | $34.31 | +48.64% | 12 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $11 | $6.04 | +82.12% | 7 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $34 | $6.14 | +453.75% | 4 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $44 | $17.41 | +152.73% | 4 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $21 → $22 | $9.52 | +131.09% | 4 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $13.74 | +118.34% | 1 | Feb 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $17 | $6.98 | +143.55% | 13 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $40 | $32.78 | +22.03% | 3 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $125 | $76.67 | +63.04% | 6 | Oct 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $2.24 | - | 1 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.50 | - | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $1.86 | - | 3 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $13 | $2.43 | +434.98% | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $80 → $90 | $4.05 | +2,122.22% | 2 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $8.52 | - | 6 | Jul 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $250 | $11.54 | +2,066.38% | 7 | Jul 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $5.61 | - | 3 | Mar 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $58 | $34.31 | +69.05% | 1 | Dec 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $7 → $12 | $11.92 | +0.67% | 2 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $29 → $37 | $4.36 | +749.60% | 6 | Oct 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $55 | $54.53 | +0.86% | 3 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $28 | $1.56 | +1,694.87% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $54 | $35.38 | +52.63% | 10 | Mar 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $0.37 | +12,058.88% | 1 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $27 | $11.64 | +132.06% | 1 | Oct 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $40 | $10.11 | +295.84% | 1 | Aug 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $133 → $137 | $429.93 | -68.13% | 9 | May 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $39 | $8.51 | +358.28% | 1 | Dec 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $29 → $48 | $5.62 | +754.09% | 5 | Jul 12, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $10.58 | - | 2 | May 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 → $18 | $0.43 | +4,047.47% | 2 | Mar 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $0.83 | +3,501.44% | 1 | Dec 4, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $45.27 | - | 2 | Nov 16, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.98 | - | 2 | Jul 21, 2017 |
Vera Therapeutics
Aug 7, 2025
Maintains: Overweight
Price Target: $56 → $53
Current: $21.14
Upside: +150.71%
Cogent Biosciences
Aug 7, 2025
Maintains: Overweight
Price Target: $29 → $30
Current: $11.56
Upside: +159.63%
Apellis Pharmaceuticals
Aug 4, 2025
Maintains: Overweight
Price Target: $35 → $37
Current: $23.90
Upside: +54.81%
Neurocrine Biosciences
Jul 31, 2025
Maintains: Neutral
Price Target: $140 → $145
Current: $128.89
Upside: +12.50%
RAPT Therapeutics
Jul 30, 2025
Upgrades: Neutral
Price Target: $14
Current: $10.90
Upside: +28.44%
Sarepta Therapeutics
Jul 29, 2025
Upgrades: Neutral
Price Target: $24
Current: $18.80
Upside: +27.66%
IDEAYA Biosciences
Jul 28, 2025
Maintains: Overweight
Price Target: $66 → $72
Current: $23.62
Upside: +204.89%
AnaptysBio
Jul 24, 2025
Maintains: Overweight
Price Target: $42 → $80
Current: $20.09
Upside: +298.21%
Replimune Group
Jul 22, 2025
Downgrades: Neutral
Price Target: $19 → $9
Current: $5.25
Upside: +71.43%
Olema Pharmaceuticals
Mar 28, 2025
Maintains: Overweight
Price Target: $30 → $28
Current: $5.31
Upside: +427.31%
Mar 27, 2025
Maintains: Overweight
Price Target: $104 → $117
Current: $28.11
Upside: +316.22%
Mar 24, 2025
Maintains: Overweight
Price Target: $44 → $50
Current: $49.09
Upside: +1.85%
Mar 20, 2025
Maintains: Overweight
Price Target: $39 → $41
Current: $12.97
Upside: +216.11%
Mar 13, 2025
Maintains: Overweight
Price Target: $44 → $51
Current: $34.31
Upside: +48.64%
Mar 13, 2025
Maintains: Overweight
Price Target: $12 → $11
Current: $6.04
Upside: +82.12%
Mar 5, 2025
Maintains: Overweight
Price Target: $39 → $34
Current: $6.14
Upside: +453.75%
Feb 26, 2025
Maintains: Overweight
Price Target: $42 → $44
Current: $17.41
Upside: +152.73%
Feb 26, 2025
Maintains: Overweight
Price Target: $21 → $22
Current: $9.52
Upside: +131.09%
Feb 25, 2025
Initiates: Overweight
Price Target: $30
Current: $13.74
Upside: +118.34%
Nov 12, 2024
Maintains: Overweight
Price Target: $16 → $17
Current: $6.98
Upside: +143.55%
Nov 5, 2024
Maintains: Overweight
Price Target: $39 → $40
Current: $32.78
Upside: +22.03%
Oct 4, 2024
Maintains: Overweight
Price Target: $100 → $125
Current: $76.67
Upside: +63.04%
Sep 30, 2024
Initiates: Neutral
Price Target: n/a
Current: $2.24
Upside: -
May 15, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.50
Upside: -
Apr 22, 2024
Upgrades: Neutral
Price Target: n/a
Current: $1.86
Upside: -
Apr 1, 2024
Maintains: Overweight
Price Target: $11 → $13
Current: $2.43
Upside: +434.98%
Aug 16, 2023
Maintains: Neutral
Price Target: $80 → $90
Current: $4.05
Upside: +2,122.22%
Jul 25, 2023
Downgrades: Underweight
Price Target: n/a
Current: $8.52
Upside: -
Jul 13, 2022
Downgrades: Neutral
Price Target: $250
Current: $11.54
Upside: +2,066.38%
Mar 8, 2022
Downgrades: Neutral
Price Target: n/a
Current: $5.61
Upside: -
Dec 10, 2021
Initiates: Overweight
Price Target: $58
Current: $34.31
Upside: +69.05%
Nov 5, 2021
Upgrades: Neutral
Price Target: $7 → $12
Current: $11.92
Upside: +0.67%
Oct 25, 2021
Upgrades: Neutral
Price Target: $29 → $37
Current: $4.36
Upside: +749.60%
Oct 12, 2021
Upgrades: Overweight
Price Target: $55
Current: $54.53
Upside: +0.86%
Aug 10, 2021
Initiates: Overweight
Price Target: $28
Current: $1.56
Upside: +1,694.87%
Mar 1, 2021
Downgrades: Neutral
Price Target: $54
Current: $35.38
Upside: +52.63%
Jan 11, 2021
Initiates: Overweight
Price Target: $45
Current: $0.37
Upside: +12,058.88%
Oct 12, 2020
Initiates: Overweight
Price Target: $27
Current: $11.64
Upside: +132.06%
Aug 18, 2020
Initiates: Overweight
Price Target: $40
Current: $10.11
Upside: +295.84%
May 7, 2020
Downgrades: Neutral
Price Target: $133 → $137
Current: $429.93
Upside: -68.13%
Dec 24, 2019
Initiates: Overweight
Price Target: $39
Current: $8.51
Upside: +358.28%
Jul 12, 2019
Downgrades: Neutral
Price Target: $29 → $48
Current: $5.62
Upside: +754.09%
May 10, 2018
Upgrades: Overweight
Price Target: n/a
Current: $10.58
Upside: -
Mar 6, 2018
Maintains: Overweight
Price Target: $15 → $18
Current: $0.43
Upside: +4,047.47%
Dec 4, 2017
Initiates: Overweight
Price Target: $30
Current: $0.83
Upside: +3,501.44%
Nov 16, 2017
Upgrades: Neutral
Price Target: n/a
Current: $45.27
Upside: -
Jul 21, 2017
Downgrades: Neutral
Price Target: n/a
Current: $0.98
Upside: -